Mark James Litton

Insider Reports History

Reporting-owner location: Bothell, WA
Latest reporting-owner signature: /s/ Mark Worthington, Attorney-in-Fact for Mark James Litton
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Mark James Litton

Form 4 holding PRESIDENT and CEO, Director

LeonaBio, Inc.

Security class: Common Stock
Shares / value: 57,926
Estimated value: $311,062
Report date: 04 Mar 2026
Price: $5.37
Ownership: Direct

Form 4 holding PRESIDENT and CEO, Director

LeonaBio, Inc.

Security class: Restricted Stock Units
Shares / value: 0
Estimated value: $125,047
Report date: 03 Mar 2026
Price: $0.5619
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding PRESIDENT and CEO, Director

LeonaBio, Inc.

Security class: Common Stock
Shares / value: 656
Estimated value: $3,004
Report date: 03 Mar 2026
Price: $4.58
Ownership: By Irrevocable Trust of OSL

Form 4 holding PRESIDENT and CEO, Director

LeonaBio, Inc.

Security class: Common Stock
Shares / value: 656
Estimated value: $3,004
Report date: 03 Mar 2026
Price: $4.58
Ownership: By Irrevocable Trust of SWL

Form 4 holding PRESIDENT and CEO, Director

LeonaBio, Inc.

Security class: Common Stock
Shares / value: 656
Estimated value: $3,004
Report date: 03 Mar 2026
Price: $4.58
Ownership: By Irrevocable Trust of WGL

Form 4 holding PRESIDENT and CEO, Director

LeonaBio, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 750,000
Estimated value
Report date: 09 Apr 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Mark James Litton

4 LONA

LeonaBio, Inc.

Report period: 09 Apr 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Apr 2026, 16:46
Role: PRESIDENT and CEO, Director
Next action: Open filing details

4 LONA

LeonaBio, Inc.

Report period: 03 Mar 2026
Transactions: 3
Transaction value: -$27,688
Accepted by SEC: 05 Mar 2026, 19:14
Role: PRESIDENT and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 31 Dec 2025
Transactions: 3
Transaction value: -$17,792
Accepted by SEC: 05 Jan 2026, 19:51
Role: President and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 24 Dec 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 29 Dec 2025, 16:17
Role: President and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 30 Jun 2025
Transactions: 3
Transaction value: -$7,374
Accepted by SEC: 02 Jul 2025, 16:34
Role: President and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 03 Mar 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Mar 2025, 16:29
Role: President and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 31 Dec 2024
Transactions: 3
Transaction value: -$14,108
Accepted by SEC: 03 Jan 2025, 17:04
Role: President and CEO, Director
Next action: Open filing details

4/A ATHA

Athira Pharma, Inc.

Report period: 03 Oct 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Oct 2024, 21:50
Role: President and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 03 Sep 2024
Transactions: 2
Transaction value: -$2,848
Accepted by SEC: 05 Sep 2024, 19:47
Role: President and CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 15 Feb 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Feb 2024, 17:05
Role: CEO, Director
Next action: Open filing details

4/A ATHA

Athira Pharma, Inc.

Report period: 04 Jan 2024
Transactions: 2
Transaction value: -$14,026
Accepted by SEC: 16 Feb 2024, 16:38
Role: CEO, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 04 Jan 2024
Transactions: 2
Transaction value: -$14,026
Accepted by SEC: 08 Jan 2024, 16:40
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 27 Jan 2023
Transactions: 2
Transaction value: +$1,814
Accepted by SEC: 31 Jan 2023, 18:33
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 22 Jun 2022
Transactions: 3
Transaction value: -$16,068
Accepted by SEC: 24 Jun 2022, 19:51
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 27 Jan 2022
Transactions: 2
Transaction value: +$11,071
Accepted by SEC: 31 Jan 2022, 16:06
Role: Chief Executive Officer, Director
Next action: Open filing details

4 ATHA

Athira Pharma, Inc.

Report period: 17 Aug 2021
Transactions: 3
Transaction value: +$80,622
Accepted by SEC: 19 Aug 2021, 17:05
Role: Chief Operating Officer
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .